Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05743595
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2023-02-14
Brief Title:
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed Unmethylated Glioblastoma
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Organization Data
Organization:
Washington University School of Medicine
Class:
OTHER
Study ID:
202307205
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Washington University School of Medicine
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Incyte Corporation | INDUSTRY |
| PapiVax Biotech Inc | OTHER |
| The Foundation for Barnes-Jewish Hospital | OTHER |